Phaseline

Companies › Suzhou Ribo Life Science

Suzhou Ribo Life Science: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Other; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RBD2080
Complement inhibitor
–Phase 1HealthySep 2027
RBD1119–Phase 1Healthy Volunteers–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07042594RBD1119Phase 1Healthy VolunteersOtherAug 2026
NCT07869940RBD2080Phase 1HealthyOtherSep 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.